Valeritas Revenue and Competitors

Bridgewater, NJ USA

Location

$355M

Total Funding

Estimated Revenue & Valuation

  • Valeritas's estimated annual revenue is currently $26.4M per year.(i)
  • Valeritas received $23.7M in venture funding in May 2016.
  • Valeritas's estimated revenue per employee is $643,854
  • Valeritas's total funding is $355M.

Employee Data

  • Valeritas has 41 Employees.(i)
  • Valeritas grew their employee count by 37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6M24-11%N/AN/A
#2
$12.8M5146%N/AN/A
#3
$13.1M528%N/AN/A
#4
$9.5M38-3%N/AN/A
#5
$2.3M929%N/AN/A
#6
$292.7M11669%N/AN/A
#7
$311.7M12422%N/AN/A
#8
$7M28-10%N/AN/A
#9
$8M3210%N/AN/A
#10
$12.6M509%N/AN/A
Add Company

We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by using one type of insulin (fast-acting) at a continuous preset (background) basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. In numerous real-world analyses V-Go has consistently shown to lower A1C's with less insulin. The discreet and convenient basal-bolus insulin delivery method provided by V-Go empowers patients to simplify their insulin management thereby mitigating the need to plan their daily routine around multiple daily injections. V-Go is cleared for use in the United States and the E.U. is commercially available in the United States.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$355M

Total Funding

41

Number of Employees

$26.4M

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Valeritas News

2022-04-20 - Wearable Injectors Market Size, Scope And Forecast ...

Valeritas, SteadyMed Therapeutics, Tandem Diabetes Care, Amgen, Medtronic, Insulet Corporation, United Therapeutic Corporation,...

2022-04-17 - Continuous Subcutaneous Insulin Infusion Market Size And ...

... Tandem Diabetes Care, CeQur, F Hoffmann-La Roche, Insulet Corporation, Ypsomed, Sooil Development, Cellenovo, Valeritas Inc.

2022-04-17 - Intramuscular Injector Market Size And Forecast | Antares ...

... International Technology, National Medical Products, Valeritas, European Pharma Group, PenJet Corporation, Becton, Dickinson.

2019-09-03 - Valeritas Announces Oral Presentation of Preclinical h-Patch ...

BRIDGEWATER, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...

2019-08-29 - Valeritas Reports Inducement Grants Under NASDAQ Listing ...

BRIDGEWATER, N.J., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.5M418%N/A
#2
$4.1M41-33%$85M
#3
$5.6M41-9%N/A
#4
$35M4214%N/A
#5
$7.5M4422%N/A

Valeritas Funding

DateAmountRoundLead InvestorsReference
2008-11-11$50.0MUndisclosedArticle
2011-09-13$150.0MCWelsh Carson Anderson and StowArticle
2013-06-05$100.0MUndisclosedCapital Royalty L PArticle
2016-05-05$23.7MUndisclosedCRG L.PArticle